Oren Gilad is the President and CEO of Aprea Therapeutics, a clinical-stage biotechnology company focused on developing synthetic lethality-based therapies.
Oren Gilad is the President and CEO of Aprea Therapeutics, a clinical-stage biotechnology company focused on developing synthetic lethality-based therapies. His leadership has included overseeing significant financing rounds and achieving IND clearance for the company's pipeline which includes ATR and WEE1 inhibitors.
Full founder directory · Investor directory · Company funding database · Fundraising library